Literature DB >> 27400944

Barriers to Quality End-of-Life Care for Patients With Blood Cancers.

Oreofe O Odejide1, Angel M Cronin2, Nolan B Condron2, Sean A Fletcher2, Craig C Earle2, James A Tulsky2, Gregory A Abel2.   

Abstract

PURPOSE: Patients with blood cancers have been shown to receive suboptimal care at the end of life (EOL) when assessed with standard oncology quality measures (eg, no chemotherapy ≤ 14 days before death). As they were developed primarily for solid tumors, it is unclear if these measures are appropriate for patients with hematologic malignancies. Moreover, barriers to high-quality EOL care for this specific patient population are largely unknown.
METHODS: In 2015, we asked a national cohort of hematologic oncologists about the acceptability of eight standard EOL quality measures. Building on prior qualitative work, we prespecified that measures achieving agreement among at least 55% of respondents would be considered acceptable. We also explored perspectives regarding barriers to quality EOL care.
RESULTS: We received 349 surveys (response rate = 57.3%). Six of the standard measures met the threshold of acceptability, and four were acceptable to > 75% of respondents: hospice admission > 7 days before death, no chemotherapy ≤ 14 days before death, no intubation in the last 30 days of life, and no cardiopulmonary resuscitation in the last 30 days of life. The highest-ranked barriers to quality EOL care reported were "unrealistic patient expectations" (97.3%), "clinician concern about taking away hope" (71.3%), and "unrealistic clinician expectations" (59.0%).
CONCLUSION: In this large national cohort of hematologic oncologists, standard EOL quality measures were highly acceptable. The top barrier to quality EOL care reported was unrealistic patient expectations, which may be best addressed with more timely and effective advance care discussions.
© 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27400944     DOI: 10.1200/JCO.2016.67.8177

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

1.  Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study.

Authors:  Nneka N Ufere; John Donlan; Lauren Waldman; Arpan Patel; Jules L Dienstag; Lawrence S Friedman; Kathleen E Corey; Nikroo Hashemi; Peter Carolan; Alan C Mullen; Michael Thiim; Irun Bhan; Ryan Nipp; Joseph Greer; Jennifer Temel; Raymond T Chung; Areej El-Jawahri
Journal:  Liver Transpl       Date:  2019-05-03       Impact factor: 5.799

2.  Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant.

Authors:  E E Eckhert; K L Schoenbeck; D Galligan; L M McNey; J Hwang; G N Mannis
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

3.  Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease.

Authors:  Nneka N Ufere; John Donlan; Lauren Waldman; Jules L Dienstag; Lawrence S Friedman; Kathleen E Corey; Nikroo Hashemi; Peter Carolan; Alan C Mullen; Michael Thiim; Irun Bhan; Ryan Nipp; Joseph A Greer; Jennifer S Temel; Raymond T Chung; Areej El-Jawahri
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-15       Impact factor: 11.382

Review 4.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Blood Adv       Date:  2017-11-28

6.  Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life.

Authors:  Rong Wang; Amer M Zeidan; Stephanie Halene; Xiao Xu; Amy J Davidoff; Scott F Huntington; Nikolai A Podoltsev; Cary P Gross; Steven D Gore; Xiaomei Ma
Journal:  J Clin Oncol       Date:  2017-08-07       Impact factor: 44.544

Review 7.  Palliative Care in Patients with Leukemia: When and How?

Authors:  Marieberta Vidal; David Hui; Eduardo Bruera
Journal:  Curr Oncol Rep       Date:  2018-11-13       Impact factor: 5.075

Review 8.  Palliative and End-of-Life Care in Myelodysplastic Syndromes.

Authors:  Myles Nickolich; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

9.  Palliative care in everyday practice of radiation oncologists : Results from a web-based survey among medical members of the German Society for Radiation Oncology (DEGRO).

Authors:  Janina Fels; Steffi Pigorsch; Hilke Vorwerk; Rita Engenhart-Cabillic; Birgitt van Oorschot
Journal:  Strahlenther Onkol       Date:  2018-11-29       Impact factor: 3.621

10.  Disparities in place of death for patients with hematological malignancies, 1999 to 2015.

Authors:  Fumiko Chino; Arif H Kamal; Junzo Chino; Thomas W LeBlanc
Journal:  Blood Adv       Date:  2019-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.